Table of Contents
Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment for Women With HER-2 Overexpressing Node-Positive Breast Cancer
N9831: Intergroup Trial for Node ?, HER2 ? Breast Cancer
Her2 Eligibility Criteria for N9831 as Determined by Local Testing
Her2 Central Testing
N9831: HER2 Testing Results
Comparison of Local/Central IHC Review
Comparison of Local/Central FISH Review
HercepTest/FISH Central Review of 119 Specimens
Comparison of Central HercepTest and Vysis FISH
Summary of Central HercepTest and Vysis FISH Results
Proposed Modifications for N9831
|
Author: Martin Kranzbaum
|